Related Experiment Videos
Processing of tumour necrosis factor-alpha precursor by metalloproteinases
A J Gearing1, P Beckett, M Christodoulou
1British Biotech, Cowley, Oxford, UK.
Nature
|August 18, 1994
Summary
Matrix metalloproteinases (MMPs) are identified as key enzymes in processing Tumour Necrosis Factor-alpha (TNF-alpha). Inhibiting these MMPs offers a novel therapeutic strategy for controlling TNF-alpha production in inflammatory diseases.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Tumour Necrosis Factor-alpha (TNF-alpha) is a critical pro-inflammatory cytokine involved in various autoimmune and infectious diseases.
- TNF-alpha exists as a membrane-bound precursor, requiring proteolytic cleavage for maturation and release.
Purpose of the Study:
- To identify the enzyme responsible for the proteolytic processing of TNF-alpha precursor.
- To explore the therapeutic potential of inhibiting this processing enzyme.
Main Methods:
- Utilized synthetic hydroxamic acid-based metalloproteinase inhibitors.
- Assessed inhibition of mature TNF-alpha release from cultured leukocytes.
- Investigated TNF-alpha release in endotoxin-challenged rats.
- Tested cleavage of recombinant TNF-alpha precursor by matrix metalloproteinase enzymes in vitro.
Main Results:
- Hydroxamic acid-based metalloproteinase inhibitors specifically blocked mature TNF-alpha release from leukocytes.
- These inhibitors also prevented TNF-alpha release in vivo in endotoxin-challenged rats.
- Matrix metalloproteinase enzymes were shown to cleave the TNF-alpha precursor into its mature form.
Conclusions:
- The processing of TNF-alpha precursor is dependent on matrix metalloproteinase-like enzymes.
- Inhibition of these enzymes represents a novel therapeutic approach to control TNF-alpha production and associated inflammatory conditions.